Dabigatran Etexilate A Pharmacoeconomic Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

作者：McKeage Kate^*

来源：PharmacoEconomics, 2012, 30(9): 841-855.

• Dabigatran etexilate
• atrial fibrillation
• cost effectiveness
• cost utility
• pharmacoeconomics
• therapeutic use

Data Selection
Sources: Medical literature (including published and unpublished data) on `dabigatran etexilate' was identified by searching databases (including MEDLINE and EMBASE) for articles published since 1996, bibliographies from published literature, clinical trial registries/databases and websites (including those of regional regulatory agencies and the manufacturer). Additional information (including contributory unpublished data) was also requested from the company developing the drug.
Search strategy: MEDLINE search terms were 'dabigatran' and 'atrial fibrillation' and ('economics' or 'health-policy' or 'quality-of-life' or 'models-statistical' or 'health-planning' or 'epidemiology' or 'guideline in pt' or 'practice-guidelines in pt'). EMBASE search terms were 'dabigatran' and ('atrial fibrillation' or 'heart atrium fibrillation') and ('economics' or 'health economics' or 'economic evaluation' or 'health status' or 'pharmacoeconomics' or 'drug cost' or 'drug utilization' or 'utilization review' or 'health survey' or 'practice guideline' or 'quality of life' or 'treatment outcome' or 'cost' or 'cost benefit analysis' or 'cost control' or 'cost effectiveness analysis' or 'cost minimisation analysis' or 'cost of illness' or 'cost utility analysis'). Searches were last updated 21 May 2012.
Selection: Economic analyses in patients with atrial fibrillation who received dabigatran etexilate. Inclusion of studies was based mainly on the methods section of the trials. Relevant background data on epidemiology and cost of illness are also included.

• 出版日期2012